pda

cis-PDA (cis PDA) is a general ionotropic receptor antagonist. cis-PDA acts by blocking NMDA, AMPA, and kainate-mediated responses.

Mycro 3 is potent and selective for c-Myc in whole cell assays.

Filaminast (UNII-CDD69JC61J) is an analog of a phosphodiesterase 4 inhibitor (PDE4 inhibitor) and roliplam, which is used as an anti-asthma drug.

12-Oxo phytodienoic acid (12-oxo PDA) is an endogenous signal converter that increases alkaloid biosynthesis in E. californica cell cultures, increases b. dioica tendril curls, And inhibited jasmonic acid-induced programmed cell death in conditioned A. fru mutants.

Cbz-TRIS-PDA is a significant compound used in research related to nucleic acids.

Cbz-TRIS-PDA (trihydrochloride) is a trifunctional compound featuring a Cbz protecting group, used in oligonucleotide synthesis.

Cbz-TRIS-PDA-OtBu is a significant compound utilized in nucleic acid-related research.

BPDA2 is a highly selective and competitive SHP2 inhibitor, exhibiting IC50 values of 92.0 nM for SHP2, and 33.39 μM and 40.71 μM for SHP1 and SHP1B, respectively. This compound effectively downregulates mitogenic and cell survival signaling, including reducing expression of receptor tyrosine kinases (RTKs). Furthermore, BPDA2 suppresses SHP2-mediated signaling, leading to the inhibition of breast cancer cell phenotypes [1].

h-NTPDase8-IN-1 is a specific aminosulfonylbenzamide inhibitor of h-NTPDases8 (IC 50 = 0.28 ± 0.07 μM). h-NTPDase8-IN-1 can be used to study diseases brought about by aberrant h -NTPDase expression.

h-NTPDase-IN-2 is a broad-spectrum NTPDase inhibitor that inhibits multiple h-NTPDas isoforms.

h-NTPDase-IN-3 is an h-NTPDase inhibitor that inhibits h-NTPDase1, h-NTPDase2, h-NTPDase3 and h-NTPDase8.

CPDA is a new potent inhibitor of SH2 domain-containing inositol phosphatase 2 (SHIP2).

TcNTPDase1-IN-1 (compound 16) serves as an inhibitor of nucleoside triphosphate diphosphohydrolase 1 (TcNTPDase1) from Trypanosoma cruzi in vitro. This compound is applicable in research related to antibacterial, antitoxic, and antitumor activities.

Subtype-selective NMDA receptor antagonist

PDAT is a noncompetitive Indolethylamine N-methyltransferase inhibitor.

NTPDase-IN-1 (compound 5a) is a selective inhibitor of NTPDase enzymes with IC50 values of 0.05 μM, 0.23 μM, and 0.54 μM against h-NTPDase-1, h-NTPDase-2, and h-NTPDase-8, respectively. It exerts non-competitive inhibition on h-NTPDase-1 and h-NTPDase-2, with a Km value of 21 μM for h-NTPDase-1. This compound is useful for investigating conditions such as cancer, immunologic disorders, and bacterial infections [1].

NTPDase-IN-3 (Compound 5e), an inhibitor of NTPDase, exhibits IC50 values of 0.38 μM (NTPDase3), 0.05 μM (NTPDase8), 0.21 μM (NTPDase1), and 1.07 μM (NTPDase2). It is utilized in cancer and thrombosis research [1].

NTPDase-IN-2 (compound 5g) selectively inhibits NTPDase-2 and NTPDase-8 with IC50 values of 0.04 µM and 2.27 µM, respectively, and exhibits non-competitive inhibition toward h-NTPDase-1 and h-NTPDase-2, with a Km of 74 µM for h-NTPDase-2. This compound is applicable in researching cancer, immunological disorders, and bacterial infections [1].

h-NTPDase-IN-4 is a pan-inhibitor of NTPDase, which can inhibit h-NTPDase1, 1h-NTPDase2, h-NTPDase3, h-NTPDase8. The IC50 values were 3.58 μM, 10.21 μM, 0.13 μM and 13.57 μM, respectively.

h-NTPDase-IN-1 (Compound 3i) is an inhibitor of human NTPDase with IC50 values of 2.88 μM for h-NTPDase1 and 0.72 μM for h-NTPDase3, indicating potential utility for thrombosis, inflammation, diabetes, and cancer research [1].

h-NTPDase-IN-5 (compound 3b) serves as a pan-inhibitor of NTPDase, exhibiting inhibitory concentration 50 (IC50) values of 1.10 μM [h-NTPDase1], 44.73 μM [h-NTPDase2], 26.14 μM [h-NTPDase3], and 0.32 μM [h-NTPDase8].

CMPDA is a positive allosteric modulator of AMPA receptors [EC50s: 45.4 nM/63.4 nM for GluA2i/GluA2o receptor].

9R,13R-Opda-CoA (9R,13R-Opda-coenzyme A) is a derivative of coenzyme A.

AOH1996 is an orally active ligand for the replicasome component PCNA (proliferating cell nuclear antigen), targeting the transcription-replication conflict (TRC). It interferes with the interaction of PCNA with its binding proteins, leading to DNA replication stress and apoptosis. AOH1996 causes proteasome-dependent rpb1 degradation and lethal DNA damage by stabilizing the interaction between PCNA and RNA polymerase II, and acts synergistically with DNA damaging agents to inhibit tumor cell growth.